<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="HALOGENATED HYDROCARBON ANESTHETICS" code="N01AB0-001" /></DRUG2>
<DESCRIPTION>Increase of the hepatotoxic effect of the isoniazid, with increased formation of its toxic metabolites.

.

</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In case of a scheduled intervention, it is prudent to stop the treatment with the isoniazid a week before the surgery and only restart it two weeks after. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of carbamazepine with signs of overdose due to inhibition of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DISULFIRAM" rxcui="3554">
<ATC code="N07BB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Disorders of behavior and of coordination</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICOIDS (EXCEPT HYDROCORTISONE)" code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Described for the prednisolone. 

Decrease of the plasma concentrations of the isoniazide. Mechanism proposed: increase of the hepatic metabolism of the isoniazide and decrease of that of the glucocorticoides</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="KETOCONAZOLE" rxcui="6135">
<ATC code="D01AC08" />
<ATC code="G01AF11" />
<ATC code="J02AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of ketoconazole</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Space the doses of the two anti-infectives at lease 12 hours apart. Monitor the plasma concentrations of the ketoconazole and possibly adjust its dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PHENYTOIN (AND, BY EXTRAPOLATION, FOSPHENYTOIN)" code="N03AB" /></DRUG2>
<DESCRIPTION>Overdose of phenytoin (decrease of its metabolism)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Strict clinical monitoring, plasma concentration dosage of phenytoin and possible adjustment of its dosage during the treatment with the isoniazid and after it is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PYRAZINAMIDE" rxcui="8987">
<ATC code="J04AK01" />
<ATC code="J04AM05" />
<ATC code="J04AM06" />
</DRUG>
</DRUG2>
<DESCRIPTION>Addition of the hepatotoxic effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RIFAMPICIN" rxcui="9384">
<ATC code="J04AB02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the hepatoxicity of the isoniazid (increase of the formation of toxic metabolites of the isoniazid)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical and biological monitoring of this classic combination. In case of hepatitis, stop the isoniazid.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>299-ISONIAZID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ISONIAZID" rxcui="6038">
<ATC code="J04AC01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STAVUDINE" rxcui="59763">
<ATC code="J05AF04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of onset of peripheral neuropathy due to addition of undesirable effects.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
</INTERACTIONS>
